WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS

Rhea-AI Summary

Willow Biosciences (TSX: WLLW, OTCQB: CANSF) held its annual general and special meeting on April 25, 2025, with 40.88% shareholder participation representing 59,214,893 common shares. Key approvals included:

• Election of 5 directors with strong majority support (84.5-88.4% approval): Dr. Chris Savile, Dr. Jim Lalonde, Donald Archibald, Raffi Asadorian, and Al Foreman
• Appointment of KPMG LLP as auditor (87.6% approval)
• Sale of Epimeron USA subsidiary (88.4% approval)
• Authorization for potential company name change to '2482118 Alberta ' (82.5% approval)

Positive

• Strong shareholder support (84.5-88.4%) for all board nominees
• High approval (88.4%) for strategic sale of Epimeron USA subsidiary

Negative

• Relatively low shareholder meeting participation at 40.88%
• Potential corporate identity change suggesting significant restructuring

SUNNYVALE, Calif., April 25, 2025 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF) is pleased to announce the voting results from its annual general and special meeting of shareholders held on April 25, 2025 (the "Meeting"). A total of 59,214,893 common shares, representing approximately 40.88% of the Company's issued and outstanding shares were represented at the meeting.

The shareholders approved the setting of the number of directors of Willow at 5 directors, and the following nominees were elected as directors of Willow for the ensuing year with the specific voting results being as follows:

	Votes For		Votes Withheld
Director	#	%	#	%
Dr. Chris Savile	46,902,346	88.3 %	6,234,676	11.7 %
Dr. Jim Lalonde	46,965,380	88.4 %	6,171,642	11.6 %
Donald Archibald	44,900,287	84.5 %	8,236,735	15.5 %
Raffi Asadorian	46,963,057	88.4 %	6,173,965	11.6 %
Al Foreman	46,900,723	88.3 %	6,236,299	11.7 %

In addition, shareholders approved the below matters. The resolutions approving the below matters may be viewed in full in the Company's management information circular dated March 26, 2025 (the "Information Circular").

	Votes For
Director	#	%
Appointment of KPMG LLP as the Company's auditor for the ensuring year	51,882,364	87.6 %
The proposed sale of the shares of Epimeron USA, Inc., the Corporation's wholly-owned subsidiary, as more particularly described in the Information Circular	46,996,397	88.4 %
To authorize the Corporation's board of directors, at its sole discretion, to amend the Articles of the Corporation to change its name from "Willow Biosciences Inc." to "2482118 Alberta Ltd.", or such other name as may be approved by the Board, as more particularly described in the Information Circular.	48,853,362	82.5 %

For complete voting results on all matters approved at the Meeting, please see the Company's Report of Voting Results dated April 25, 2025, available on SEDAR+ at www.sedarplus.ca.

About Willow Biosciences Inc.

Willow develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Willow's FutureGrown^TM biotechnology platform allows large-scale production with sustainability at its core. Willow's R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers.

For more information, visit www.willowbio.com or contact:

Travis Doupe
Chief Financial Officer
E: info@willowbio.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/willow-biosciences-announces-annual-general-and-special-meeting-voting-results-302438831.html

SOURCE Willow Biosciences Inc.

FAQ

What were the key voting results from Willow Biosciences (CANSF) 2025 annual meeting?

Shareholders approved the election of 5 directors with 84.5-88.4% support, appointed KPMG LLP as auditor (87.6%), approved Epimeron USA sale (88.4%), and authorized potential name change (82.5%).

What is the significance of Willow Biosciences (CANSF) selling Epimeron USA?

Shareholders approved the sale of Epimeron USA subsidiary with 88.4% support, indicating strong shareholder agreement with this strategic divestment.

Why is Willow Biosciences (CANSF) considering changing its name to 2482118 Alberta ?

The board received authorization (82.5% approval) to change the company name, suggesting a potential corporate restructuring or strategic shift.

What was the shareholder participation rate at Willow Biosciences' 2025 annual meeting?

The meeting had 40.88% shareholder participation, with 59,214,893 common shares represented.